Free Trial
LON:SBTX

SkinBioTherapeutics (SBTX) Share Price, News & Analysis

SkinBioTherapeutics logo
GBX 15.66
-1.05 (-6.26%)
(As of 12:21 PM ET)

About SkinBioTherapeutics Stock (LON:SBTX)

Key Stats

Today's Range
15.58
16.55
50-Day Range
10.38
18.15
52-Week Range
7
27.54
Volume
819,609 shs
Average Volume
975,966 shs
Market Capitalization
£35.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.

Receive SBTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SkinBioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

SBTX Stock News Headlines

Skinbiotherap. Share Chat (SBTX)
If you missed the last crypto boom, you have to see this
A massive regulatory move is expected in the very near future… That could send a specific few cryptos soaring. And while the crypto market is highly volatile… and we can’t promise against losses or guarantee future returns…. We see this as THE BIGGEST opportunity in the crypto market in many years. The first crypto revolution started with Bitcoin… and a few savvy traders had a shot at absolutely outrageous 14,510% gains or more
ProBiotix Health Plc (PBX.AQ)
SkinBioTherapeutics plc (SBTX.L)
SkinBioTherapeutics bags £3m at a modest discount
See More Headlines

SBTX Stock Analysis - Frequently Asked Questions

SkinBioTherapeutics' stock was trading at GBX 15.25 at the start of the year. Since then, SBTX shares have increased by 2.7% and is now trading at GBX 15.66.
View the best growth stocks for 2024 here
.

SkinBioTherapeutics plc (LON:SBTX) announced its quarterly earnings results on Tuesday, March, 3rd. The company reported ($0.64) EPS for the quarter.

Shares of SBTX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that SkinBioTherapeutics investors own include OptiBiotix Health (OPTI), Ecora Resources (ECOR), Avacta Group (AVCT), Inspired (INSE), Lb-shell (LBP), Anglo African Oil & Gas (AAOG) and Avino Silver & Gold Mines (ASM).

Company Calendar

Last Earnings
3/03/2020
Today
11/04/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
11
Year Founded
N/A

Profitability

Net Income
£-2,880,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£21,949.00
Cash Flow
GBX 1.74 per share
Book Value
GBX 2 per share

Miscellaneous

Free Float
N/A
Market Cap
£35.39 million
Optionable
Not Optionable
Beta
2.01
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (LON:SBTX) was last updated on 11/4/2024 by MarketBeat.com Staff
From Our Partners